In this classification system, the primary genetic markers for gliomas are IDH mutation status, codeletion of chromosomal arms 1p and 19q (1p/19q codeletion), nuclear alpha-thalassemia/mental retardation X-linked syndrome (ATRX) gene mutations, O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status, loss of cyclin-dependent kinase inhibitor 2A (CDKN2A), epidermal growth factor receptor (EGFR) amplification and telomerase reverse transcriptase (TERT) promoter mutations. This evidence concerns the gene CDKN2A and central nervous system cancer.